PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Inclusion Criteria: * Has provided written informed consent, and has the willingness and ability to comply with all study procedures * \>= 18 years old * Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation * Neutropenic fever is defined as the presence of neutropenia defined by: * Absolute neutrophil count (ANC) \< 500 cells/mm3 or has an ANC that is expected to decrease to \< 500 cells/mm\^3 within 48 hours of trial entry and fever defined as: * Single oral temperature measurement of \> 100.4 degree F (38.0 degree C). * Requires hospitalization for IV empiric antibiotic therapy * If female: * Not breastfeeding * Agrees to not attempt to become pregnant during the study. Is surgically sterile or at least 2-years postmenopausal, or if of childbearing potential, has negative screening serum or urine pregnancy test within 5 days * If of childbearing potential (including being \< 2 years postmenopausal), is willing to practice sexual abstinence or use an effective dual form of contraception with her partner (eg, 2 barrier methods, barrier method plus hormonal method) during treatment and up 28 days post treatment Exclusion Criteria: * History of any hypersensitivity or allergic reaction to any carbapenem * Fever suspected to be caused by a noninfectious cause (eg, fever related to drug or blood product administration) * Confirmed fungal infection (eg, Pneumocystis jirovecii etiology in patients with p…